Form 4: Tharimmune, Inc. Executive Granted Stock Options

Sireesh Appajosyula, Chief Operating Officer of Tharimmune, Inc., was granted options to purchase 38,087 shares of common stock on August 9, 2024.

Summary

• On August 9, 2024, Sireesh Appajosyula, the Chief Operating Officer of Tharimmune, Inc., received options to acquire 38,087 shares of the company's common stock.
• The options were granted under the company's 2023 Omnibus Equity Incentive Plan.
• The exercise price of the options is $2.925 per share.
• The options vest in 12 equal monthly installments, starting on the grant date.
• The options expire on August 9, 2034.
• Following the transaction, Appajosyula directly owns 63,087 derivative securities.

Sentiment

Score: 7

Explanation: The sentiment is neutral to slightly positive. The granting of stock options is a common practice and generally viewed as a positive sign of aligning management interests with shareholders.

Positives

• The granting of stock options to the COO aligns his interests with those of the shareholders.
• The vesting schedule incentivizes the COO to remain with the company for at least one year.

Industry Context

Stock option grants are a common practice in the pharmaceutical industry to incentivize executives and align their interests with shareholders.

Stakeholder Impact

• Shareholders may view the option grant as a positive sign, aligning management's interests with theirs.
• Employees may be motivated by the fact that key executives are incentivized to improve company performance.

Key Dates

Keywords

stock options, Form 4, insider trading, Sireesh Appajosyula, Tharimmune, Inc., equity incentive plan, COO, THAR